A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Shiryaev, S A ^a   Remacle, A G ^a   Golubkov, V S ^a   Ingvarsen, S ^b   Porse, A ^b   Behrendt, N ^b   Cieplak, P ^a   Strongin, A Y ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; Monoclonal antibody; MT1 MMP; Proteinase inhibitor; TIMP 2

Indexed keywords

GELATINASE A; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 25; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9E8; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY COMBINING SITE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CELL ASSAY; COMPLEMENTARITY DETERMINING REGION; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; EPITOPE MAPPING; HUMAN; HUMAN CELL; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; SURFACE PROPERTY;

MURINAE;

EID: 84890402516     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.44     Document Type: Article

References (38)

1. Gomis-Ruth FX. Catalytic domain architecture of metzincin metalloproteases. J Biol Chem 2009; 284: 15353-15357.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
3. Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006; 206: 1-8.
4. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the threedimensional extracellular matrix. Cell 2003; 114: 33-45.
5. Yana I, Seiki M. MT-MMPs play pivotal roles in cancer dissemination. Clin Exp Metastasis 2002; 19: 209-215.
6. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA et al. MT1- MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999; 99: 81-92.
7. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010; 1803: 55-71.
8. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992; 267: 4583-4591.
9. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He CS. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci USA 1989; 86: 8207-8211.
10. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65.
11. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-5338.
12. Zucker S, Pei D, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol 2003; 54: 1-74.
13. Ingvarsen S, Porse A, Erpicum C, Maertens L, Jurgensen HJ, Madsen DH et al. Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis. J Biol Chem 2013; 288: 10195-10204.
14. Devy L, Dransfield DT. New Strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem Res Int 2011; 2011: 191670.
15. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009; 69: 1517-1526.
16. Kaimal R, Aljumaily R, Tressel SL, Pradhan RV, Covic L, Kuliopulos A et al. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res 2013; 73: 2457-2467.
17. Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem 2001; 276: 37491-37500.
18. Golubkov VS, Chekanov AV, Shiryaev SA, Aleshin AE, Ratnikov BI, Gawlik K et al. Proteolysis of the membrane type-1 matrix metalloproteinase prodomain: implications for a two-step proteolytic processing and activation. J Biol Chem 2007; 282: 36283-36291.
19. Williamson RA, Hutton M, Vogt G, Rapti M, Knauper V, Carr MD et al. Tyrosine 36 plays a critical role in the interaction of the AB loop of tissue inhibitor of metalloproteinases-2 with matrix metalloproteinase-14. J Biol Chem 2001; 276: 32966-32970.
20. Golubkov VS, Strongin AY. Insights into ectodomain shedding and processing of protein-tyrosine pseudokinase 7 (PTK7). J Biol Chem 2012; 287: 42009-42018.
21. Golubkov VS, Aleshin AE, Strongin AY. Potential relation of aberrant proteolysis of human protein tyrosine kinase 7 (PTK7) chuzhoi by membrane type 1 matrix metalloproteinase (MT1-MMP) to congenital defects. J Biol Chem 2011; 286: 20970-20976.
22. Golubkov VS, Chekanov AV, Cieplak P, Aleshin AE, Chernov AV, Zhu W et al. The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis. J Biol Chem 2010; 285: 35740-35749.
23. English WR, Holtz B, Vogt G, Knauper V, Murphy G. Characterization of the role of the 'MT-loop': an eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases. J Biol Chem 2001; 276: 42018-42026.
24. Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 1998; 273: 1216-1222.
25. Remacle AG, Chekanov AV, Golubkov VS, Savinov AY, Rozanov DV, Strongin AY. Oglycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP). J Biol Chem 2006; 281: 16897-16905.
26. Rozanov DV, Deryugina EI, Monosov EZ, Marchenko ND, Strongin AY. Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane type-1 matrix metalloproteinase in malignant cells. Exp Cell Res 2004; 293: 81-95.
27. Rozanov DV, Strongin AY. Membrane type-1 matrix metalloproteinase functions as a proprotein self-convertase. Expression of the latent zymogen in Pichia pastoris, autolytic activation, and the peptide sequence of the cleavage forms. J Biol Chem 2003; 278: 8257-8260.
28. Toth M, Hernandez-Barrantes S, Osenkowski P, Bernardo MM, Gervasi DC, Shimura Y et al. Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme. J Biol Chem 2002; 277: 26340-26350.
29. Remacle AG, Shiryaev SA, Golubkov VS, Freskos JN, Brown MA, Karwa AS et al. Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells. J Biol Chem 2013; 288: 20568-20580.
30. Kridel SJ, Sawai H, Ratnikov BI, Chen EI, Li W, Godzik A et al. A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. J Biol Chem 2002; 277: 23788-23793.
31. Shiryaev SA, Savinov AY, Cieplak P, Ratnikov BI, Motamedchaboki K, Smith JW et al. Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One 2009; 4: e4952.
32. Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DG et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol 2002; 319: 173-181.
33. Tanaka T, Williams RL, Rabbitts TH. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J 2007; 26: 3250-3259.
34. Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A et al. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 1998; 17: 5238-5248.
35. Pierce BG, Hourai Y, Weng Z. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS One 2011; 6: e24657.
36. Sali A, Potterton L, Yuan F, van Vlijmen H, Karplus M. Evaluation of comparative protein modeling by MODELLER. Proteins 1995; 23: 318-326.
37. Ye Y, Godzik A. FATCAT: a web server for flexible structure comparison and structure similarity searching. Nucleic Acids Res 2004; 32: W582-W585.
38. Lang R, Braun M, Sounni NE, Noel A, Frankenne F, Foidart JM et al. Crystal structure of the catalytic domain of MMP-16/MT3-MMP: characterization of MT-MMP specific features. J Mol Biol 2004; 336: 213-225.